Results 1 to 10 of about 160,580 (263)

CRISPR Cas9 in Pancreatic Cancer Research

Frontiers in Cell and Developmental Biology, 2019
Pancreatic cancer is now becoming a common cause of cancer death with no significant change in patient survival over the last 10 years. The main treatment options for pancreatic cancer patients are surgery, radiation therapy and chemotherapy, but there ...
Hai Yang, Peter Bailey, Christian Pilarsky   +2 more
doaj   +1 more source

UGI relocation inside Cas9 reduces Cas9 dependent off target effects in cytosine base editors

Scientific Reports
Cytosine base editors (CBEs) achieve precise C-to-T conversions by addition of uracil DNA glycosylase inhibitor (UGI) with Cas9 nickase (nCas9) and cytidine deaminase, and the conventional fusion at the nCas9 carboxyl terminus effectively inhibits uracil
Zehao Shi, Tian-Lin Cheng
doaj   +1 more source

Optimized Plasmid Construction Strategy for Cas9

Cellular Physiology and Biochemistry, 2018
Background/Aims: The target genome editing technology not only plays an important role in basic biology studies but also holds a great promise for potential clinical applications.
Jianyong  Xu, Wenlei Li, MD. Munnaf  Hossen, Yuning Jia, Lingyun Li, Zhong Huang   +5 more
doaj   +1 more source

Development of an RNA aptamer-assisted CRISPR/Cas9 system for efficiently generating and isolating Cas9-free mutants in plant.

PLoS Genetics
The CRISPR/Cas9 gene-editing system is a powerful tool in plant genetic engineering; however, screening for Cas9-free edited plants remains complex and time-consuming.
Sha Liu, Jiuyuan Bai, Bo Zhan, Junyu Yao, Jiayu Zhang, Jia Yi, Mengyue Dong, Qicong Li, Yucheng Shen, Yazhou Chen, Yun Zhao   +10 more
doaj   +1 more source

CRISPR/Cas9, a universal tool for genomic engineering

Вавиловский журнал генетики и селекции, 2016
The CRISPR/Cas9 system was initially described as an element of archeal and bacterial immunity, but gained much attention recently for its outstanding ability to be programmed to target any genomic loci through a short 20-nucleotide sgRNA region. Here we
A. V. Smirnov, A. M. Yunusova, V. A. Lukyanchikova, N. R. Battulin   +3 more
doaj   +1 more source

In vivo evaluation of guide-free Cas9-induced safety risks in a pig model

Signal Transduction and Targeted Therapy
The CRISPR/Cas9 system has shown great potential for treating human genetic diseases through gene therapy. However, there are concerns about the safety of this system, specifically related to the use of guide-free Cas9.
Weikai Ge, Shixue Gou, Xiaozhu Zhao, Qin Jin, Zhenpeng Zhuang, Yu Zhao, Yanhui Liang, Zhen Ouyang, Xiaoyi Liu, Fangbing Chen, Hui Shi, Haizhao Yan, Han Wu, Liangxue Lai, Kepin Wang   +14 more
doaj   +1 more source

Assessment of a Split Homing Based Gene Drive for Efficient Knockout of Multiple Genes

G3: Genes, Genomes, Genetics, 2020
Nikolay P. Kandul, Junru Liu, Anna Buchman, Valentino M. Gantz, Ethan Bier, Omar S. Akbari   +5 more
doaj   +1 more source

Highly stable Cas9 promotes HBV genome destruction by antagonizing HSC70-mediated degradation

Emerging Microbes and Infections
As a naturally existing adaptive immune system of prokaryotes against phages and foreign genetic materials, the CRISPR/Cas9 system has been widely used to combat various viral infections.
Zhongqing Li, Yarong Song, Hongxin Huang, Ran Chen, Mingchen Liu, Xingwen Yang, Ziheng Luo, Benjamin M. Liu, Jie Wang   +8 more
doaj   +1 more source

Targeting Cas9 [PDF]

Nature Methods, 2018
openaire   +2 more sources

Visualization of a multi-turnover Cas9 after product release

Nature Communications
While the most widely used CRISPR-Cas enzyme is the Cas9 endonuclease from Streptococcus pyogenes (Cas9), it exhibits single-turnover enzyme kinetics which leads to long residence times on product DNA.
Kaitlyn A. Kiernan, David W. Taylor
doaj   +1 more source